Squarepoint
ABUS icon

Squarepoint’s Arbutus Biopharma ABUS Stock Holding History

Squarepoint’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,000
Closed -$87.3K – 4421
2025
Q1 		$87.3K Buy
+25,000
New +$83.4K ﹤0.01% 4255
2024
Q4 		– Sell
-1,270,000
Closed -$4.89M – 4966
2024
Q3 		$4.89M Sell
1,270,000
-175,000
-12% -$671K 0.01% 1436
2024
Q2 		$4.47M Hold
1,445,000
– – 0.01% 1454
2024
Q1 		$3.73M Buy
+1,445,000
New +$3.74M 0.01% 1663

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's ABUS Position: Q2 2026 in Review

Squarepoint opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 208,145 shares worth $999K. The stake represents ﹤0.01% of the portfolio and ranks #2891 among its holdings. This is a return to the name: Squarepoint previously reported a position in ABUS as recently as Q4 2025.

Squarepoint first reported a position in ABUS in Q4 2016 and has held it in 17 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Squarepoint held 208,145 shares of Arbutus Biopharma worth $999K as of Q2 2026.
  • Arbutus Biopharma was a new Squarepoint position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2891 holding.
  • Squarepoint first reported a position in Arbutus Biopharma in Q4 2016 and has held it in 17 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.